NRG1 and schizophrenia: Previous works showed that administration of anti-Nrg1 antibodies induced schizophrenia-like behavioral phenotypes (including hyper-locomotion and impaired pre-pulse inhibition of startle) and altered synaptic transmission in adult mice [49, 50].